Motens (Lacidipine)

Lacidipine, the active ingredient in Motens, is a calcium channel blocker presented as a tablet for oral use. It lowers elevated blood pressure by relaxing vascular smooth muscle, and is prescribed for adult patients with hypertension.

GNH USA supplies Motens as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its global distribution network ensures timely delivery and compliance with local regulatory requirements.

Lacidipine is used to manage hypertension, a condition characterized by chronically elevated arterial pressure.

Hypertension: reduces systolic and diastolic blood pressure, improving cardiovascular risk profile. Essential hypertension: provides sustained blood pressure control in patients without an identifiable secondary cause. Isolated systolic hypertension: lowers systolic pressure especially in elderly patients.

Lacidipine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth and redness, usually temporary. - Peripheral edema: swelling of ankles or feet due to fluid accumulation. - Dizziness or light‑headedness, especially after standing. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Angioedema: rapid swelling of face, lips, tongue, or airway. - Myocardial infarction: rare occurrence of heart attack. - Significant liver enzyme elevation. - Severe bradycardia or arrhythmia. - Allergic reactions such as rash or anaphylaxis.

When prescribing Lacidipine, clinicians should consider several safety measures.

Monitor blood pressure regularly: adjust therapy if target levels are not achieved. Avoid abrupt discontinuation: tapering reduces rebound hypertension. Caution in hepatic impairment: dose adjustment may be required. Use cautiously in elderly patients: increased sensitivity to hypotensive effects. Avoid concurrent strong CYP3A4 inhibitors: may raise drug concentrations. Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Lacidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Concomitant use with other antihypertensives (e.g., ACE inhibitors, ARBs) may cause additive hypotension. - Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or clarithromycin can increase Lacidipine plasma levels. - Grapefruit juice: may elevate drug concentration and risk of adverse effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce therapeutic effect. - Diuretics: may enhance blood‑pressure‑lowering effect, requiring monitoring. - Beta‑blockers: combined use may affect heart rate and blood pressure. - NSAIDs: may attenuate antihypertensive response.